Everolimus in advanced or metastatic breast cancer.

In one trial, combination therapy with everolimus and exemestane prolonged progression-free survival a few months (on the basis of radiological studies) compared with exemestane alone, which is not the standard treatment. However, the addition of everolimus greatly increased the incidence of serious adverse effects. As of mid-2013, the effect on overall survival is uncertain.